Zydus Lifesciences quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	8,017	6,574	+22.0%
EBITDA	1,929	2,089	−7.6%
EBITDA margin	24.1%	31.8%	−7.7 pts
Profit before tax	1,307	1,921	−32.0%
Net profit	990	1,521	−34.9%
EPS	₹9.35	₹14.58	−35.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	8,017	7,587	6,865	6,123	6,574	6,528	5,269	5,237	6,208	5,534	4,505	4,369	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	106	134	111	109	155	80.6	57.5	68.2	63.2	156	37.7	54.0
	8,123	7,721	6,976	6,232	6,729	6,609	5,327	5,305	6,271	5,690	4,543	4,423
	1,251	1,347	1,216	1,327	1,219	1,164	1,027	1,067	1,116	1,210	1,063	1,037
	1,289	972	852	589	658	573	571	484	522	543	459	406
	−301	−343	−232	−226	−87.6	−39.9	−14.2	−79.0	−51.8	−142	−54.1	31.3
	1,368	1,239	1,140	1,034	1,005	971	947	879	884	837	817	753
	156	123	130	101	84.7	76.6	32.0	25.1	32.2	34.6	19.8	8.7
	555	508	360	302	238	238	229	234	215	205	195	184
	2,480	1,818	2,072	1,383	1,691	1,734	1,352	1,425	1,654	1,455	1,117	996
	6,798	5,664	5,538	4,511	4,808	4,717	4,143	4,034	4,371	4,143	3,617	3,416
	1,929	2,554	1,816	2,016	2,089	2,126	1,388	1,461	2,084	1,631	1,102	1,146
	1,375	2,046	1,457	1,714	1,850	1,888	1,159	1,228	1,869	1,425	908	962
Profit
	1,325	2,057	1,438	1,722	1,921	1,892	1,184	1,271	1,900	1,547	926	1,007
	−18.2	−398	−84.9	−34.2	0.0	−220	0.0	0.0	0.0	0.0	0.0	0.0
	1,307	1,660	1,353	1,687	1,921	1,672	1,184	1,271	1,900	1,547	926	1,007
	376	526	244	379	231	991	39.3	366	654	465	150	253
	−21.7	−207	144	75.2	203	−567	140	7.5	−218	−144	64.1	−26.9
	354	318	388	454	434	423	180	373	436	321	214	226
	37.8	−0.3	57.8	5.2	34.4	−5.1	21.9	22.1	18.9	17.1	56.4	23.4
	990	1,341	1,023	1,239	1,521	1,244	1,026	920	1,483	1,246	790	803
	952	1,341	965	1,233	1,487	1,249	1,005	898	1,464	1,226	712	781
	0.0	0.0	0.0	0.0	0.0	0.0	−0.3	0.3	0.0	3.2	21.8	−1.0
	−32.5	−483	−21.8	−275	4.9	−22.8	−43.1	−10.5	−23.6	−171	20.3	−56.1
	958	858	1,001	964	1,526	1,221	983	910	1,459	1,076	810	747
	940	1,273	1,042	1,259	1,467	72.8	1,024	911	1,420	63.8	790	801
	50.4	68.5	−19.2	−20.0	54.2	1,171	2.7	9.0	62.6	1,182	0.3	2.5
Per share
	₹9.35	₹12.65	₹10.36	₹12.51	₹14.58	₹11.64	₹10.17	₹9.06	₹14.11	₹11.69	₹7.80	₹7.91
	₹9.35	₹12.65	₹10.36	₹12.51	₹14.58	₹11.64	₹10.17	₹9.06	₹14.11	₹11.69	₹7.80	₹7.91
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	0.0	0.0	−0.4	0.4	0.0	4.1	27.7	−1.3
	0.0	0.0	0.0	0.0	0.0	0.0	−0.1	0.1	0.0	0.9	5.9	−0.3
Other comprehensive income — detail
	−32.5	−483	−21.8	−275	4.9	−22.8	—	—	—	—	—	—
	26.3	−69.4	20.1	19.5	−3.1	11.2	−7.2	−21.3	10.1	−32.6	−1.2	−16.6
	0.8	16.5	−1.1	−0.2	−1.7	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	−1.4	−5.5	0.2	−2.4	−1.3	−2.4
	−58.0	−398	−43.0	−294	6.3	−34.0	−37.3	5.3	−33.5	−140	20.2	−41.9
	912	790	1,021	984	1,472	72.6	980	901	1,396	1,012	810	745
	45.7	67.4	−20.2	−20.0	54.2	1,148	2.7	9.0	62.6	63.8	0.3	2.5
Per share — as-filed variants
	₹9.35	₹12.65	₹10.36	₹12.51	₹14.58	₹11.64	₹10.18	₹9.05	₹14.11	₹11.66	₹7.59	₹7.92
	₹9.35	₹12.65	₹10.36	₹12.51	₹14.58	₹11.64	₹10.18	₹9.05	₹14.11	₹11.66	₹7.59	₹7.92
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	−₹0.01	₹0.01	₹0.00	₹0.03	₹0.21	−₹0.01
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	−₹0.01	₹0.01	₹0.00	₹0.03	₹0.21	−₹0.01
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	5,777	5,611	5,028	4,433	4,784	4,831	3,686	3,766	4,621	3,922	3,037	2,895
	72.1%	74.0%	73.2%	72.4%	72.8%	74.0%	69.9%	71.9%	74.4%	70.9%	67.4%	66.3%
Adjusted (ex-exceptional items) — derived
	1,325	2,057	1,438	1,722	1,921	1,892	1,184	1,271	1,900	1,547	926	1,007
	−18.2	−398	−84.9	−34.2	0.0	−220	0.0	0.0	0.0	0.0	0.0	0.0
	1,003	1,662	1,083	1,264	1,521	1,408	1,026	920	1,483	1,246	790	803
	₹9.48	₹15.68	₹10.97	₹12.76	₹14.58	₹13.18	₹10.17	₹9.06	₹14.11	₹11.69	₹7.80	₹7.91

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZYDUSLIFE₹1,175.50

Zydus Lifesciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA DRREDDY CIPLA TORNTPHARM DIVISLAB MAXHEALTH APOLLOHOSP AUROPHARMAMcap ₹1.18L Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	4,368.8	4,505.2	5,533.8	6,207.5	5,237.0	5,269.1	6,527.9	6,573.7	6,123.2	6,864.5	7,587.0	8,017.0
Other Income	54.0	37.7	156.4	63.2	68.2	57.5	80.6	154.9	109.0	111.4	134.2	106.1
Total Income	4,422.8	4,542.9	5,690.2	6,270.7	5,305.2	5,326.6	6,608.5	6,728.6	6,232.2	6,975.9	7,721.2	8,123.1
Expenses
+ Cost of Materials Consumed	1,037.0	1,063.2	1,210.3	1,115.5	1,066.5	1,026.5	1,164.4	1,218.9	1,327.1	1,216.4	1,347.2	1,251.2
+ Purchases of Stock-in-Trade	405.5	459.4	542.9	522.4	483.9	571.1	572.6	658.2	589.1	851.5	971.7	1,289.2
+ Changes in Inventories	31.3	-54.1	-141.7	-51.8	-79.0	-14.2	-39.9	-87.6	-225.7	-231.6	-342.6	-300.6
+ Employee Benefit Expense	752.9	817.3	837.0	883.5	879.2	946.5	971.4	1,005.2	1,034.2	1,139.7	1,238.8	1,368.2
+ Finance Costs	8.7	19.8	34.6	32.2	25.1	32.0	76.6	84.7	101.3	129.9	123.0	156.0
+ Depreciation & Amortisation	184.2	194.8	205.3	215.3	233.6	229.0	237.9	238.1	301.9	359.6	508.4	554.7
+ Other Expenses	996.0	1,117.0	1,454.8	1,653.9	1,425.0	1,351.6	1,733.9	1,690.5	1,382.7	2,072.1	1,817.5	2,479.6
Total Expenses	3,415.6	3,617.4	4,143.2	4,371.0	4,034.3	4,142.5	4,716.9	4,808.0	4,510.6	5,537.6	5,664.0	6,798.3
EBITDA	1,146.1	1,102.4	1,630.5	2,084.0	1,461.4	1,387.6	2,125.5	2,088.5	2,015.8	1,816.4	2,554.4	1,929.4
EBIT	961.9	907.6	1,425.2	1,868.7	1,227.8	1,158.6	1,887.6	1,850.4	1,713.9	1,456.8	2,046.0	1,374.7
Profit
PBT before Exceptional Items	1,007.2	925.5	1,547.0	1,899.7	1,270.9	1,184.1	1,891.6	1,920.6	1,721.6	1,438.3	2,057.2	1,324.8
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	-219.6	0.0	-34.2	-84.9	-397.5	-18.2
Pretax Income	1,007.2	925.5	1,547.0	1,899.7	1,270.9	1,184.1	1,672.0	1,920.6	1,687.4	1,353.4	1,659.7	1,306.6
+ Current Tax	253.3	149.7	464.9	653.8	365.6	39.3	990.6	230.7	378.8	244.4	525.6	375.9
+ Deferred Tax	-26.9	64.1	-143.7	-217.7	7.5	140.2	-567.4	203.3	75.2	143.9	-207.2	-21.7
Tax Expense	226.4	213.8	321.2	436.1	373.1	179.5	423.2	434.0	454.0	388.3	318.4	354.2
+ Share of Associates & JVs	23.4	56.4	17.1	18.9	22.1	21.9	-5.1	34.4	5.2	57.8	-0.3	37.8
Net Income	803.2	789.9	1,246.1	1,482.5	920.2	1,026.2	1,243.7	1,521.0	1,238.6	1,022.9	1,341.0	990.2
+ Net Income — Continuing Ops	780.8	711.7	1,225.8	1,463.6	897.8	1,004.6	1,248.8	1,486.6	1,233.4	965.1	1,341.3	952.4
+ Net Income — Discontinued Ops	-1.0	21.8	3.2	0.0	0.3	-0.3	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	-56.1	20.3	-170.5	-23.6	-10.5	-43.1	-22.8	4.9	-274.5	-21.8	-483.4	-32.5
Total Comprehensive Income	747.1	810.2	1,075.6	1,458.9	909.7	983.1	1,220.9	1,525.9	964.1	1,001.1	857.6	957.7
Net Income to Common	800.7	789.6	63.8	1,419.9	911.2	1,023.5	72.8	1,466.8	1,258.6	1,042.1	1,272.5	939.8
Minority Interest	2.5	0.3	1,182.3	62.6	9.0	2.7	1,170.9	54.2	-20.0	-19.2	68.5	50.4
Per Share
Basic EPS	7.91	7.80	11.69	14.11	9.06	10.17	11.64	14.58	12.51	10.36	12.65	9.35
Diluted EPS	7.91	7.80	11.69	14.11	9.06	10.17	11.64	14.58	12.51	10.36	12.65	9.35
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	-1.3	27.7	4.1	0.0	0.4	-0.4	0.0	0.0	0.0	0.0	0.0	0.0
+ Tax — Discontinued Operations	-0.3	5.9	0.9	0.0	0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-22.8	4.9	-274.5	-21.8	-483.4	-32.5
+ Items NOT to be Reclassified to P&L	-16.6	-1.2	-32.6	10.1	-21.3	-7.2	11.2	-3.1	19.5	20.1	-69.4	26.3
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	-1.7	-0.2	-1.1	16.5	0.8
+ Tax on Items NOT to be Reclassified — alt tag	-2.4	-1.3	-2.4	0.2	-5.5	-1.4	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-41.9	20.2	-140.3	-33.5	5.3	-37.3	-34.0	6.3	-294.2	-43.0	-397.5	-58.0
Comprehensive Income — Owners of Parent	744.6	809.9	1,011.8	1,396.3	900.7	980.4	72.6	1,471.7	984.1	1,021.3	790.2	912.0
Comprehensive Income — Non-controlling Interests	2.5	0.3	63.8	62.6	9.0	2.7	1,148.3	54.2	-20.0	-20.2	67.4	45.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	7.92	7.59	11.66	14.11	9.05	10.18	11.64	14.58	12.51	10.36	12.65	9.35
Diluted EPS — Continuing Operations	7.92	7.59	11.66	14.11	9.05	10.18	11.64	14.58	12.51	10.36	12.65	9.35
Basic EPS — Discontinued Operations	-0.01	0.21	0.03	0.00	0.01	-0.01	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	-0.01	0.21	0.03	0.00	0.01	-0.01	0.00	0.00	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,895.0	3,036.7	3,922.3	4,621.4	3,765.6	3,685.7	4,830.8	4,784.2	4,432.7	5,028.2	5,610.7	5,777.2
Gross Margin %	66.27	67.40	70.88	74.45	71.90	69.95	74.00	72.78	72.39	73.25	73.95	72.06
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,007.2	925.5	1,547.0	1,899.7	1,270.9	1,184.1	1,891.6	1,920.6	1,721.6	1,438.3	2,057.2	1,324.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	-219.6	0.0	-34.2	-84.9	-397.5	-18.2
Net Income Adj (tax-effected)	803.2	789.9	1,246.1	1,482.5	920.2	1,026.2	1,407.7	1,521.0	1,263.6	1,083.4	1,662.2	1,003.5
EPS Adj	7.91	7.80	11.69	14.11	9.06	10.17	13.18	14.58	12.76	10.97	15.68	9.48
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	101.2	101.2	100.6	100.6	100.6	100.6	100.6	100.6	100.6	100.6	100.6	99.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Zydus Lifesciences Q2 FY27 results date

Zydus Lifesciences (NSE: ZYDUSLIFE) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 19 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹940 crore, down 35.9% from ₹1,467 crore in Q1 FY26 and down 26.1% from ₹1,273 crore in Q4 FY26. Revenue from operations was ₹8,017 crore, up 22.0% year on year and up 5.7% from the previous quarter.

Board-meeting notice filed: 19 October 2026
Q2 FY26 results (a year earlier): 6 November 2025
Q1 FY27 results (the latest): 11 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 19 Oct
Q1 FY27 net profit: ₹940 Cr−35.9% vs Q1 FY26−26.1% vs Q4 FY26
Q1 FY27 revenue: ₹8,017 Cr+22.0% vs Q1 FY26+5.7% vs Q4 FY26
Q1 FY27 operating margin: 17.1%−11.0 pts vs Q1 FY26−9.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹1,259 CrRevenue ₹6,123 Cr
Q1 FY27 EPS (basic): ₹9.35

Questions

When will Zydus Lifesciences announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 19 October 2026). Last year it reported Q2 FY26 on 6 November 2025.

What were Zydus Lifesciences' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹940 crore, down 35.9% from ₹1,467 crore in Q1 FY26 and down 26.1% from ₹1,273 crore in Q4 FY26. Revenue from operations was ₹8,017 crore, up 22.0% year on year and up 5.7% from the previous quarter.

What was Zydus Lifesciences' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹5,040 crore in FY26 (April 2025–March 2026). It was ₹113 crore in FY24 and ₹1,960 crore in FY23: up 157.1% over three years, 37.0% a year on average.

What will Zydus Lifesciences' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹1,259 crore and revenue from operations ₹6,123 crore. The latest quarter, Q1 FY27, had a net profit of ₹940 crore and revenue of ₹8,017 crore.

How has Zydus Lifesciences' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹1,259 crore in Q2 FY26, ₹1,042 crore in Q3 FY26, ₹1,273 crore in Q4 FY26 and ₹940 crore in Q1 FY27. That is ₹4,513 crore over the four quarters, up 29.9% from ₹3,474 crore in the four quarters before. Revenue from operations: ₹6,123 crore, ₹6,865 crore, ₹7,587 crore and ₹8,017 crore.

What was Zydus Lifesciences' revenue in FY26?

Revenue from operations was ₹27,148 crore in FY26 (April 2025–March 2026), up 16.8% from ₹23,242 crore in FY25. It was ₹19,547 crore in FY24 and ₹17,237 crore in FY23: up 57.5% over three years, 16.3% a year on average.

Where do these Zydus Lifesciences figures come from?

From Zydus Lifesciences' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.